HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $313,000 | -2.2% | 7,500 | 0.0% | 0.02% | -8.3% |
Q4 2020 | $320,000 | +59.2% | 7,500 | 0.0% | 0.02% | +50.0% |
Q2 2020 | $201,000 | -74.5% | 7,500 | -82.7% | 0.02% | -76.1% |
Q3 2018 | $789,000 | +7.8% | 43,417 | 0.0% | 0.07% | +1.5% |
Q2 2018 | $732,000 | -14.0% | 43,417 | 0.0% | 0.07% | -16.5% |
Q1 2018 | $851,000 | – | 43,417 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |